Influence of G protein-biased agonists of μ-opioid receptor on addiction-related behaviors.
Addiction
Dependence
G protein-biased opioids
Reward
Tolerance
Μ-opioid receptor
Journal
Pharmacological reports : PR
ISSN: 2299-5684
Titre abrégé: Pharmacol Rep
Pays: Switzerland
ID NLM: 101234999
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
31
01
2021
accepted:
16
03
2021
revised:
05
03
2021
pubmed:
10
4
2021
medline:
19
1
2022
entrez:
9
4
2021
Statut:
ppublish
Résumé
Opioid analgesics remain a gold standard for the treatment of moderate to severe pain. However, their clinical utility is seriously limited by a range of adverse effects. Among them, their high-addictive potential appears as very important, especially in the context of the opioid epidemic. Therefore, the development of safer opioid analgesics with low abuse potential appears as a challenging problem for opioid research. Among the last few decades, different approaches to the discovery of novel opioid drugs have been assessed. One of the most promising is the development of G protein-biased opioid agonists, which can activate only selected intracellular signaling pathways. To date, discoveries of several biased agonists acting via μ-opioid receptor were reported. According to the experimental data, such ligands may be devoid of at least some of the opioid side effects, such as respiratory depression or constipation. Nevertheless, most data regarding the addictive properties of biased μ-opioid receptor agonists are inconsistent. A global problem connected with opioid abuse also requires the search for effective pharmacotherapy for opioid addiction, which is another potential application of biased compounds. This review discusses the state-of-the-art on addictive properties of G protein-biased μ-opioid receptor agonists as well as we analyze whether these compounds can diminish any symptoms of opioid addiction. Finally, we provide a critical view on recent data connected with biased signaling and its implications to in vivo manifestations of addiction.
Identifiants
pubmed: 33835467
doi: 10.1007/s43440-021-00251-1
pii: 10.1007/s43440-021-00251-1
pmc: PMC8413226
doi:
Substances chimiques
Analgesics, Opioid
0
Receptors, Opioid
0
GTP-Binding Proteins
EC 3.6.1.-
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1033-1051Subventions
Organisme : Narodowe Centrum Nauki
ID : 2018/31/B/NZ7/03954
Organisme : Narodowe Centrum Nauki
ID : 2020/36/T/NZ7/00476
Informations de copyright
© 2021. The Author(s).
Références
Pain. 2018 Sep;159(9):1705-1718
pubmed: 29708942
Eur J Pharmacol. 2015 Jul 5;758:11-5
pubmed: 25843409
Biol Psychiatry. 2020 Dec 15;88(12):935-944
pubmed: 32305216
Br J Anaesth. 2020 Oct;125(4):596-604
pubmed: 32819621
Pain. 2021 Feb 1;162(2):432-445
pubmed: 32826750
J Neurosci. 2011 Sep 28;31(39):13890-6
pubmed: 21957251
Pharmacol Rev. 2017 Jul;69(3):256-297
pubmed: 28626043
Expert Opin Pharmacother. 2009 Aug;10(11):1727-40
pubmed: 19538000
Psychopharmacology (Berl). 2018 Oct;235(10):2823-2829
pubmed: 30039246
Sci Rep. 2017 Mar 14;7:44247
pubmed: 28290478
Cell. 2017 Nov 16;171(5):1165-1175.e13
pubmed: 29149605
Mol Pharmacol. 2015 Aug;88(2):335-46
pubmed: 26013541
Neuropsychopharmacology. 2020 Jan;45(2):416-425
pubmed: 31443104
Br J Anaesth. 2019 Jun;122(6):e136-e145
pubmed: 31010646
Pharmacol Biochem Behav. 1990 Jan;35(1):231-5
pubmed: 2315362
Eur J Pharmacol. 2006 Nov 7;549(1-3):63-70
pubmed: 16978601
Anesthesiology. 2011 Dec;115(6):1363-81
pubmed: 22020140
J Clin Pharmacol. 2018 Jun;58(6):750-761
pubmed: 29412458
J Med Chem. 2016 Sep 22;59(18):8381-97
pubmed: 27556704
Mol Pharmacol. 2007 Feb;71(2):549-57
pubmed: 17090705
Science. 1999 Dec 24;286(5449):2495-8
pubmed: 10617462
Drug Alcohol Depend. 2020 Mar 1;208:107849
pubmed: 32029298
Pharmacol Rev. 2011 Dec;63(4):1001-19
pubmed: 21873412
J Clin Pharmacol. 2014 Mar;54(3):351-7
pubmed: 24122908
Drug Alcohol Depend. 2006 Sep 15;84(2):175-81
pubmed: 16517095
Pain. 2014 Sep;155(9):1829-1835
pubmed: 24954166
J Cardiovasc Pharmacol. 2017 Sep;70(3):142-158
pubmed: 28328745
Front Pharmacol. 2019 Apr 17;10:407
pubmed: 31057409
Biol Psychiatry. 2014 Nov 15;76(10):767-74
pubmed: 24629717
J Pharmacol Exp Ther. 1990 Dec;255(3):1027-32
pubmed: 2175793
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11820-11828
pubmed: 32393639
J Neurosci. 2003 Nov 12;23(32):10265-73
pubmed: 14614085
Br J Pharmacol. 2018 Jul;175(13):2653-2661
pubmed: 29582414
Cell Mol Neurobiol. 2021 Jul;41(5):1131-1143
pubmed: 33433723
Science. 2005 Apr 22;308(5721):512-7
pubmed: 15845844
Addiction. 2008 Jun;103(6):1048-50
pubmed: 18482427
Neuron. 2007 Aug 2;55(3):365-76
pubmed: 17678851
Science. 2017 Mar 3;355(6328):966-969
pubmed: 28254944
Br J Pharmacol. 2019 Sep;176(17):3110-3125
pubmed: 31074038
Neuropsychopharmacology. 2011 Feb;36(3):551-8
pubmed: 20980993
Life Sci. 2004 Mar 12;74(17):2143-55
pubmed: 14969718
Pain Pract. 2019 Sep;19(7):715-731
pubmed: 31162798
J Psychopharmacol. 2017 Jun;31(6):730-739
pubmed: 28142305
Pain. 2016 Jan;157(1):264-272
pubmed: 26683109
Nature. 2000 Dec 7;408(6813):720-3
pubmed: 11130073
Curr Pharm Des. 2012;18(2):128-44
pubmed: 22229559
Pharmacol Rev. 2019 Apr;71(2):267-315
pubmed: 30914442
Psychopharmacology (Berl). 2015 Jul;232(13):2227-38
pubmed: 25616583
J Pharmacol Exp Ther. 2005 Sep;314(3):1195-201
pubmed: 15917400
Neuropsychopharmacology. 2007 Sep;32(9):1995-2003
pubmed: 17251906
Biol Psychiatry. 2020 Jan 1;87(1):15-21
pubmed: 31806082
Psychopharmacology (Berl). 2009 Dec;207(3):413-22
pubmed: 19816677
Anesth Analg. 2019 Nov;129(5):1414-1421
pubmed: 30044299
Drug Alcohol Depend. 2018 Nov 1;192:158-162
pubmed: 30261403
Neuropharmacology. 2021 Mar 1;185:108439
pubmed: 33345829
ACS Omega. 2019 Oct 09;4(17):17457-17476
pubmed: 31656918
Nat Rev Drug Discov. 2018 Apr;17(4):243-260
pubmed: 29302067
Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:143-159
pubmed: 28968188
Br J Anaesth. 2011 Nov;107(5):774-81
pubmed: 21926413
ACS Chem Neurosci. 2015 Sep 16;6(9):1570-7
pubmed: 26148793
Br J Pharmacol. 2004 Jan;141(1):55-64
pubmed: 14662727
Expert Opin Drug Discov. 2014 Nov;9(11):1345-54
pubmed: 25307021
Life Sci. 2005 Nov 19;78(1):2-7
pubmed: 16169018
J Pharmacol Exp Ther. 2010 Mar;332(3):1127-35
pubmed: 20008489
Transl Psychiatry. 2020 May 28;10(1):167
pubmed: 32522999
Neuropharmacology. 2008 Aug;55(2):154-65
pubmed: 18550129
Mol Pain. 2017 Jan-Dec;13:1744806917740030
pubmed: 29056067
Pharmacol Ther. 2006 Jun;110(3):465-502
pubmed: 16460808
Mol Pharmacol. 2020 Oct;98(4):410-424
pubmed: 32665252
J Pharmacol Exp Ther. 2013 Mar;344(3):708-17
pubmed: 23300227
Neuropsychopharmacology. 2019 Feb;44(3):465-477
pubmed: 30293087
Neuropharmacology. 2019 May 15;150:200-209
pubmed: 30660628
Br J Pharmacol. 2011 Oct;164(4):1322-34
pubmed: 21434879
Nat Commun. 2019 Jan 21;10(1):367
pubmed: 30664663
J Pharmacol Exp Ther. 2020 Feb;372(2):224-236
pubmed: 31594792
Neurosci Lett. 2002 Jun 7;325(2):107-10
pubmed: 12044633
Front Pharmacol. 2014 Dec 18;5:280
pubmed: 25566076
Front Pharmacol. 2020 Jul 15;11:1078
pubmed: 32760281
Mol Pharmacol. 2019 Nov;96(5):542-549
pubmed: 31175184
Molecules. 2020 Aug 25;25(17):
pubmed: 32854452
ACS Chem Neurosci. 2020 Jun 17;11(12):1781-1790
pubmed: 32383854
Biomed Res Int. 2015;2015:968786
pubmed: 26640804
Trends Pharmacol Sci. 2020 Dec;41(12):947-959
pubmed: 33097283
Br J Pharmacol. 2020 Apr;177(7):1497-1513
pubmed: 31705528
Molecules. 2020 Sep 16;25(18):
pubmed: 32948048
Int J Drug Policy. 2010 Jul;21(4):283-8
pubmed: 20092998
Br J Pharmacol. 2013 Aug;169(7):1430-46
pubmed: 23646826
Anesth Analg. 2005 Sep;101(3):728-734
pubmed: 16115983
J Ethnopharmacol. 2019 Apr 6;233:34-40
pubmed: 30594604
JAMA Psychiatry. 2019 Feb 1;76(2):208-216
pubmed: 30516809
Expert Opin Investig Drugs. 2018 Oct;27(10):765-775
pubmed: 30148648
Nature. 2016 Sep 8;537(7619):185-190
pubmed: 27533032
Behav Brain Res. 2017 Feb 15;319:96-103
pubmed: 27818236
Mol Pharmacol. 1987 Nov;32(5):633-8
pubmed: 2824980
Annu Rev Physiol. 2007;69:483-510
pubmed: 17305471
J Pharmacol Exp Ther. 1989 Jul;250(1):1-8
pubmed: 2526212
Br J Pharmacol. 2019 Dec;176(23):4434-4445
pubmed: 31347704
Behav Brain Res. 2019 Mar 15;360:146-157
pubmed: 30500430
Neuropharmacology. 2011 Jan;60(1):58-65
pubmed: 20713067
Nat Rev Drug Discov. 2017 Dec;16(12):829-842
pubmed: 29075003
Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):12072-7
pubmed: 23818586
Pain Physician. 2018 Jul;21(4):309-326
pubmed: 30045589
Prog Mol Biol Transl Sci. 2016;137:203-27
pubmed: 26810003
Sci Rep. 2018 Jun 12;8(1):8965
pubmed: 29895890
Drug Alcohol Depend. 2009 Oct 1;104(3):187-96
pubmed: 19497686
Sci Signal. 2020 Mar 31;13(625):
pubmed: 32234959
Public Health Rep. 2018 Nov/Dec;133(1_suppl):24S-34S
pubmed: 30426871
Addict Biol. 2007 Sep;12(3-4):227-462
pubmed: 17678505
Addict Biol. 2019 Sep;24(5):874-885
pubmed: 29949228
Nature. 2005 Dec 8;438(7069):854-7
pubmed: 16341013
Br J Pharmacol. 2020 Jul;177(13):2923-2931
pubmed: 32052419
Cochrane Database Syst Rev. 2016 May 09;(5):CD011117
pubmed: 27157143
Nat Protoc. 2007;2(11):2987-95
pubmed: 18007634
Dialogues Clin Neurosci. 2017 Sep;19(3):247-258
pubmed: 29302222
Addiction. 2007 Dec;102(12):1863-70
pubmed: 18031422
J Pharmacol Exp Ther. 2021 Mar;376(3):410-427
pubmed: 33384303
Int J Mol Sci. 2019 Sep 02;20(17):
pubmed: 31480739